Bahamas

Medicines and pharmacy oversight in The Bahamas is carried out through the Ministry of Health and Wellness and the Bahamas Pharmacy Council under the Pharmacy Act. The Bahamas also uses the regional CARPHA VigiCarib system for suspected adverse drug reactions and medical-product quality reports, with reports routed to the relevant national office for follow-up. A standalone public national GVP guideline establishing MAH-specific requirements for a local QPPV, PSMF, fixed ICSR timelines, PSUR/PBRER schedules, or RMP submission was not identified in current official sources. These requirements are therefore not established as mandatory without confirmation from the competent Bahamian authority for the relevant product. Where the cited public sources do not expressly define signal management and audit and inspection arrangements, the MAH should confirm the current product-specific requirements with the competent authority and against the marketing-authorisation conditions. BAUPHARMA supporting resources (operational context only, not national regulatory evidence): Effective Signal Management in Pharmacovigilance.